Pfizer Sees Promise in Obesity Treatment, Sets Stage for 2028 Approval

Pfizer has released promising phase two trial data on its experimental obesity treatment, PF′3944. The injection drove solid weight loss in a mid-stage trial, with patients losing up to 12.3% of their weight compared to placebo. Pfizer plans to start 10 phase three studies and aims for approvals in 2028. The company believes the monthly product has a "very competitive profile" in tolerability and efficacy, with potential "best-in-class" efficacy and tolerability data. Pfizer is focused on bringing to market treatments from its $10 billion acquisition of Metsera.